With the advent of novel pipeline molecules, the global MDS market expected to surpass US $1,500 million by 2019, says Technavio
This market research report from Technavio segments the global myelodysplastic syndrome (MDS) market by class of drugs (alkylating agents, cytotoxic antibiotics, topoisomerase inhibitors, and others), by route of administration (oral and parenteral), and by geography (APAC, EMEA, and the Americas). Leading vendors analysed in this market study are Celgene, Novartis, and Otsuka. Technavio’s market…
